Experiences with Jardiance

This page shows detailed information about a medicine such as statistics, patient reviews and related articles.

Active ingredient: empagliflozin
ATC Code: A10BK03

Level of
Satisfaction

Level of Satisfaction 91%

What patients say...

Effectiveness 91%
Quantity of side effects 0%
Severity of side effects 0%
Ease of use 91%

Our patients

Our patients, demographics

Read our patient's reviews about Jardiance

Filter reviews by...

hide filters...
translation feature available for reviews from other countries
Jardiance
11/07/2017 | | 69moderated by Charlotte
empagliflozin (10mg) for diabetes type 2

Been taking this medicine for 8 days now. My blood sugar has gone from 14.5 to 8.1 mmol/l. Pretty stunning result.
> read full review...

Jardiance
11/07/2017 | | 57moderated by Philip
empagliflozin (10mg) for diabetes type 2

My blood sugars were always too high, but this pill has made a huge difference. Really so happy with it and I have to inject less often which is also obviously a bonus.
> read full review...

Jardiance
20/06/2017 | | 51moderated by Susan
empagliflozin (10mg) for diabetes type 2

Adjusting took a few weeks and now I am so glad I did persist because the result is amazing. My blood glucose values have never been this good in the last 25 years.
> read full review...

Most reviewed medicines


The content on this page is user-generated content, read and revised before approval to comply with our standards for a medicine review or reaction. We do not enforce any proven medical knowledge from our users to allow them to present their experiences. This way, the opinions and experiences described state only the views of the writers and not those of the owner of this website. Remember that these experiences differ from person to person and that you should always contact your doctor or pharmacist for advice on medication.

Copyright © 2008-2024 Insight Pharma Services BV.
All rights reserved.
Most icons from FontAwesome. Some icons made by Prosymbols from www.flaticon.com and licensed as CC 3.0 BY.